{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:05:28Z","timestamp":1747713928309,"version":"3.40.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00415-025-13100-5","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:25:34Z","timestamp":1746264334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8802-4914","authenticated-orcid":false,"given":"David","family":"Herman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3806-2413","authenticated-orcid":false,"given":"Julien","family":"Tanniou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-4499","authenticated-orcid":false,"given":"Emmanuelle","family":"Leray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2702-3343","authenticated-orcid":false,"given":"Chloe","family":"Pierret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Pilard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"13100_CR1","unstructured":"MS International Federation (2020) MS International Federation. 2020 [cited 2024 Mar 8]. Atlas of MS 2020\u2014Epidemiology report. Available from: https:\/\/www.msif.org\/resource\/atlas-of-ms-2020\/"},{"issue":"11","key":"13100_CR2","doi-asserted-by":"publisher","first-page":"1073278","DOI":"10.3389\/fpubh.2023.1073278","volume":"17","author":"Z Qian","year":"2023","unstructured":"Qian Z, Li Y, Guan Z, Guo P, Zheng K, Du Y et al (2023) Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019. Front Public Health 17(11):1073278","journal-title":"Front Public Health"},{"issue":"14","key":"13100_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler Houndmills Basingstoke Engl. 26(14):1816\u201321","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"Suppl 1","key":"13100_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000367614","volume":"72","author":"FD Lublin","year":"2014","unstructured":"Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl 1):1\u20135","journal-title":"Eur Neurol"},{"issue":"3","key":"13100_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/JMAU.JMAU_59_18","volume":"7","author":"FO Kamel","year":"2019","unstructured":"Kamel FO (2019) Factors involved in relapse of multiple sclerosis. J Microsc Ultrastruct 7(3):103","journal-title":"J Microsc Ultrastruct"},{"issue":"2","key":"13100_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40273-020-00964-w","volume":"39","author":"L Hernandez","year":"2021","unstructured":"Hernandez L, O\u2019Donnell M, Postma M (2021) Predictors of health utility in relapsing-remitting and secondary-progressive multiple sclerosis: implications for future economic models of disease-modifying therapies. Pharmacoeconomics 39(2):243\u2013256","journal-title":"Pharmacoeconomics"},{"key":"#cr-split#-13100_CR7.1","unstructured":"B\u016bhler A (2019) Comparison of time-to-first-event and recurrent event methods in multiple sclerosis trials [Internet]. arXiv"},{"key":"#cr-split#-13100_CR7.2","unstructured":"2019 [cited 2024 Jan 17]. Available from: http:\/\/arxiv.org\/abs\/2111.01937"},{"key":"13100_CR8","doi-asserted-by":"publisher","unstructured":"Reeve K, On BI, Havla J, Burns J, Gosteli-Peter MA, Alabsawi A, et al. Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev [Internet]. 2023 [cited 2024 Mar 18]. Available from: https:\/\/www.cochranelibrary.com\/cdsr. https:\/\/https:\/\/doi.org\/10.1002\/14651858.CD013606.pub2\/full","DOI":"10.1002\/14651858.CD013606.pub2\/full"},{"issue":"11","key":"13100_CR9","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D et al (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138(11):3287\u20133298","journal-title":"Brain"},{"issue":"9","key":"13100_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/13524585231189671","volume":"29","author":"RA Marrie","year":"2023","unstructured":"Marrie RA, Sormani MP, Apap Mangion S, Bovis F, Cheung WY, Cutter GR et al (2023) Improving the efficiency of clinical trials in multiple sclerosis. Mult Scler J 29(9):1136\u20131148","journal-title":"Mult Scler J"},{"issue":"11","key":"13100_CR11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"issue":"1","key":"13100_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jns.2009.07.017","volume":"285","author":"YC Wang","year":"2009","unstructured":"Wang YC, Meyerson L, Tang YQ, Qian N (2009) Statistical methods for the analysis of relapse data in MS clinical trials. J Neurol Sci 285(1):206\u2013211","journal-title":"J Neurol Sci"},{"issue":"2014","key":"13100_CR13","volume":"4","author":"AM Lavery","year":"2014","unstructured":"Lavery AM, Verhey LH, Waldman AT (2014) Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int 4(2014):e262350","journal-title":"Mult Scler Int"},{"issue":"8","key":"13100_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jech.2004.030759","volume":"59","author":"J Twisk","year":"2005","unstructured":"Twisk J, Smidt N, de Vente W (2005) Applied analysis of recurrent events: a practical overview. J Epidemiol Commun Health 59(8):706\u2013710","journal-title":"J Epidemiol Commun Health"},{"issue":"2","key":"13100_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cegh.2019.01.013","volume":"7","author":"M Thenmozhi","year":"2019","unstructured":"Thenmozhi M, Jeyaseelan V, Jeyaseelan L, Isaac R, Vedantam R (2019) Survival analysis in longitudinal studies for recurrent events: applications and challenges. Clin Epidemiol Glob Health 7(2):253\u2013260","journal-title":"Clin Epidemiol Glob Health"},{"issue":"1","key":"13100_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/ije\/dyu222","volume":"44","author":"LD Amorim","year":"2015","unstructured":"Amorim LD, Cai J (2015) Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol 44(1):324\u2013333","journal-title":"Int J Epidemiol"},{"issue":"6","key":"13100_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/pst.2032","volume":"19","author":"CP Yadav","year":"2020","unstructured":"Yadav CP, Lodha R, Kabra SK, Sreenivas V, Sinha A, Khan MA et al (2020) Comparison of statistical methods for recurrent event analysis using pediatrics asthma data. Pharm Stat 19(6):803\u2013813","journal-title":"Pharm Stat"},{"key":"13100_CR18","doi-asserted-by":"publisher","unstructured":"Cook RJ, Lawless J (2007) The statistical analysis of recurrent events [Internet]. Springer, New York. 2007 [cited 2024 Feb 13]. (Statistics for Biology and Health). Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-0-387-69810-6","DOI":"10.1007\/978-0-387-69810-6"},{"issue":"4","key":"13100_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"PK Andersen","year":"1982","unstructured":"Andersen PK, Gill RD (1982) Cox\u2019s regression model for counting processes: a large sample study. Ann Stat 10(4):1100\u20131120","journal-title":"Ann Stat"},{"issue":"1","key":"13100_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<13::AID-SIM279>3.0.CO;2-5","volume":"19","author":"PJ Kelly","year":"2000","unstructured":"Kelly PJ, Lim LL (2000) Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med 19(1):13\u201333","journal-title":"Stat Med"},{"issue":"2","key":"13100_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/biom.12761","volume":"74","author":"S Kim","year":"2018","unstructured":"Kim S, Schaubel DE, McCullough KP (2018) A C-index for recurrent event data: application to hospitalizations among dialysis patients. Biometrics 74(2):734\u2013743","journal-title":"Biometrics"},{"key":"13100_CR22","doi-asserted-by":"publisher","unstructured":"Charles-Nelson A, Katsahian S, Schramm C (2019) How to analyze and interpret recurrent events data in the presence of a terminal event: An application on readmission after colorectal cancer surgery\u2014Charles\u2010Nelson\u20142019\u2014Statistics in Medicine\u2014Wiley Online Library. 2019 [cited 2024 Feb 13]; Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/sim.8168","DOI":"10.1002\/sim.8168"},{"key":"#cr-split#-13100_CR23.1","unstructured":"Rogers DJ (2016) The analysis of recurrent events: A summary of methodology. Statisticians in the Pharmaceutical Industry (PSI)"},{"key":"#cr-split#-13100_CR23.2","unstructured":"[cited 2025 Apr 29]. Available from: https:\/\/www.psiweb.org\/docs\/defaultsource\/resources\/psi-subgroups\/scientific\/archive\/2016\/time-to-event-and-recurrent-event-endpoints\/jrogers.pdf"},{"issue":"1","key":"13100_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ejhf.29","volume":"16","author":"JK Rogers","year":"2014","unstructured":"Rogers JK, Pocock SJ, McMurray JJV, Granger CB, Michelson EL, \u00d6stergren J et al (2014) Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-preserved. Eur J Heart Fail 16(1):33\u201340","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"13100_CR25","first-page":"437","volume":"107","author":"G Rauch","year":"2018","unstructured":"Rauch G, Kieser M, Binder H, Bayes-Genis A, Jahn-Eimermacher A (2018) Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints. Clin Res Cardiol Off J Ger Card Soc 107(5):437\u2013443","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"key":"13100_CR26","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2020) Qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses. 2020 European Medicines Agengy (EMA). Committee for Medicinal Products for Human Use (CHMP)."},{"issue":"1","key":"13100_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/13524585221125382","volume":"29","author":"A B\u00fchler","year":"2023","unstructured":"B\u00fchler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M et al (2023) Recurrent disability progression endpoints in multiple sclerosis clinical trials. Mult Scler Houndmills Basingstoke Engl 29(1):130\u2013139","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"6","key":"13100_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","volume":"138","author":"B Claggett","year":"2018","unstructured":"Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD (2018) Comparison of time-to-first event and recurrent-event methods in randomized clinical trials. Circulation 138(6):570\u2013577","journal-title":"Circulation"},{"issue":"22","key":"13100_CR29","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1093\/eurheartj\/ehs277","volume":"33","author":"SD Anker","year":"2012","unstructured":"Anker SD, McMurray JJV (2012) Time to move on from \u2018time-to-first\u2019: should all events be included in the analysis of clinical trials? Eur Heart J 33(22):2764\u20132765","journal-title":"Eur Heart J"},{"issue":"3","key":"13100_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/2168479018784912","volume":"53","author":"M Akacha","year":"2019","unstructured":"Akacha M, Binkowitz B, Claggett B, Hung HMJ, Mueller-Velten G, Stockbridge N (2019) Assessing treatment effects that capture disease burden in serious chronic diseases. Ther Innov Regul Sci 53(3):387\u2013397","journal-title":"Ther Innov Regul Sci"},{"key":"13100_CR31","unstructured":"Seker BIO, Reeve K, Havla J, Burns J, Gosteli MA, Lutterotti A, et al. (2020) Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev [Internet]. 2020 [cited 2024 Mar 18]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7389149\/"},{"key":"13100_CR32","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (2023) Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023) [Internet]. 2023 [cited 2024 Apr 25]. Available from: www.training.cochrane.org\/handbook."},{"key":"13100_CR33","unstructured":"Critical Path Institute (2024) Multiple sclerosis outcome assessments consortium (MSOAC) [Internet]. 2024 [cited 2024 Feb 21]. Available from: https:\/\/c-path.org\/multiple-sclerosis-outcome-assessments-consortium-msoac-placebo-database-faq\/"},{"issue":"10","key":"13100_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1212\/WNL.0000000000004330","volume":"89","author":"J Lorscheider","year":"2017","unstructured":"Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E et al (2017) Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology 89(10):1050\u20131059","journal-title":"Neurology"},{"issue":"2","key":"13100_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/13524585211017013","volume":"28","author":"A Kalinowski","year":"2022","unstructured":"Kalinowski A, Cutter G, Bozinov N, Hinman JA, Hittle M, Motl R et al (2022) The timed 25-foot walk in a large cohort of multiple sclerosis patients. Mult Scler J 28(2):289\u2013299","journal-title":"Mult Scler J"},{"issue":"7","key":"13100_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(10)70094-6","volume":"9","author":"SV Ramagopalan","year":"2010","unstructured":"Ramagopalan SV, Dobson R, Meier UC, Giovannoni G (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 9(7):727\u2013739","journal-title":"Lancet Neurol"},{"issue":"12","key":"13100_CR37","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.2215\/CJN.12841216","volume":"12","author":"W Yang","year":"2017","unstructured":"Yang W, Jepson C, Xie D, Roy JA, Shou H, Hsu JY et al (2017) Statistical methods for recurrent event analysis in cohort studies of CKD. Clin J Am Soc Nephrol 12(12):2066","journal-title":"Clin J Am Soc Nephrol"},{"key":"13100_CR38","doi-asserted-by":"crossref","unstructured":"Keene. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited\u2014PubMed. 2008 [cited 2024 Feb 9]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18591336\/","DOI":"10.1183\/09031936.00161507"},{"issue":"2","key":"13100_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jvs.2014.02.051","volume":"60","author":"X Yang","year":"2014","unstructured":"Yang X, Lu X, Li W, Huang Y, Huang X, Lu M et al (2014) Endovascular treatment for symptomatic stent failures in long-segment chronic total occlusion of femoropopliteal arteries. J Vasc Surg 60(2):362\u2013368","journal-title":"J Vasc Surg"},{"issue":"1","key":"13100_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2288-11-80","volume":"11","author":"MN Mieno","year":"2011","unstructured":"Mieno MN, Yamaguchi T, Ohashi Y (2011) Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials. BMC Med Res Methodol 11(1):80","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"13100_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0022-510X(99)00015-5","volume":"163","author":"MP Sormani","year":"1999","unstructured":"Sormani MP, Bruzzi P, Miller DH, Gasperini C, Barkhof F, Filippi M (1999) Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 163(1):74\u201380","journal-title":"J Neurol Sci"},{"issue":"3","key":"13100_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"1","key":"13100_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/pst.1910","volume":"18","author":"JH Roger","year":"2019","unstructured":"Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON (2019) Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. Pharm Stat 18(1):85\u201395","journal-title":"Pharm Stat"},{"issue":"2","key":"13100_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3414\/ME0478","volume":"47","author":"Z Guo","year":"2008","unstructured":"Guo Z, Gill TM, Allore HG (2008) Modeling repeated time-to-event health conditions with discontinuous risk intervals: an example of a longitudinal study of functional disability among older persons. Methods Inf Med 47(2):107\u2013116","journal-title":"Methods Inf Med"},{"key":"13100_CR45","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2147\/COPD.S141646","volume":"12","author":"F Rassouli","year":"2017","unstructured":"Rassouli F, Baty F, Stolz D, Albrich WC, Tamm M, Widmer S et al (2017) Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk. Int J Chron Obstruct Pulmon Dis 12:3103\u20133109","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"11","key":"13100_CR46","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jamaneurol.2020.2453","volume":"77","author":"N Lizak","year":"2020","unstructured":"Lizak N, Malpas CB, Sharmin S, Havrdova EK, Horakova D, Izquierdo G et al (2020) Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. JAMA Neurol 77(11):1398\u20131407","journal-title":"JAMA Neurol"},{"issue":"10","key":"13100_CR47","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/ckj\/sfad029","volume":"16","author":"N Marx","year":"2023","unstructured":"Marx N, Wanner C, Jankowski J, M\u00e4rz W, Krane V, Genser B (2023) Recurrent cardiovascular events in patients with type 2 diabetes and haemodialysis: analysis from the 4D Study. Clin Kidney J 16(10):1612\u20131621","journal-title":"Clin Kidney J"},{"issue":"2","key":"13100_CR48","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s10479-020-03884-2","volume":"315","author":"MK Lintu","year":"2022","unstructured":"Lintu MK, Kamath A (2022) Performance of recurrent event models on defect proneness data. Ann Oper Res 315(2):2209\u20132218","journal-title":"Ann Oper Res"},{"issue":"1","key":"13100_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12874-021-01475-8","volume":"22","author":"N Patson","year":"2022","unstructured":"Patson N, Mukaka M, Kazembe L, Eijkemans MJC, Mathanga D, Laufer MK et al (2022) Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study. BMC Med Res Methodol 22(1):24","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"13100_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0962280206071926","volume":"16","author":"C Metcalfe","year":"2007","unstructured":"Metcalfe C, Thompson SG (2007) Wei, Lin and Weissfeld\u2019s marginal analysis of multivariate failure time data: should it be applied to a recurrent events outcome? Stat Methods Med Res 16(2):103\u2013122","journal-title":"Stat Methods Med Res"},{"issue":"25","key":"13100_CR51","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.jacc.2009.08.035","volume":"54","author":"MJ Tikkanen","year":"2009","unstructured":"Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O et al (2009) Total cardiovascular disease burden: comparing intensive with moderate statin therapy: insights from the IDEAL (incremental decrease in end points through aggressive lipid lowering) trial. J Am Coll Cardiol 54(25):2353\u20132357","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"13100_CR52","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ejhf.1139","volume":"20","author":"UM Mogensen","year":"2018","unstructured":"Mogensen UM, Gong J, Jhund PS, Shen L, K\u00f8ber L, Desai AS et al (2018) Effect of sacubitril\/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 20(4):760\u2013768","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"13100_CR53","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pst.2167","volume":"21","author":"JK Furberg","year":"2022","unstructured":"Furberg JK, Rasmussen S, Andersen PK, Ravn H (2022) Methodological challenges in the analysis of recurrent events for randomised controlled trials with application to cardiovascular events in LEADER. Pharm Stat 21(1):241\u2013267","journal-title":"Pharm Stat"},{"issue":"3","key":"13100_CR54","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","volume":"76","author":"Y Naegelin","year":"2019","unstructured":"Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ et al (2019) Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurol 76(3):274\u2013281","journal-title":"JAMA Neurol"},{"issue":"17","key":"13100_CR55","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"2","key":"13100_CR56","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000334771","volume":"33","author":"F Purroy","year":"2012","unstructured":"Purroy F, Jim\u00e9nez Caballero PE, Gorospe A, Torres MJ, Alvarez-Sabin J, Santamarina E et al (2012) Prediction of early stroke recurrence in transient ischemic attack patients from the PROMAPA study: a comparison of prognostic risk scores. Cerebrovasc Dis Basel Switz 33(2):182\u2013189","journal-title":"Cerebrovasc Dis Basel Switz"},{"issue":"4","key":"13100_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/1352458517695468","volume":"24","author":"MS Freedman","year":"2018","unstructured":"Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE et al (2018) The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Mult Scler Houndmills Basingstoke Engl 24(4):535\u2013539","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"1","key":"13100_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41512-024-00173-5","volume":"8","author":"V Watson","year":"2024","unstructured":"Watson V, Smith CT, Bonnett LJ (2024) Systematic review of methods used in prediction models with recurrent event data. Diagn Progn Res 8(1):13","journal-title":"Diagn Progn Res"},{"issue":"1","key":"13100_CR59","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12884-022-04948-w","volume":"22","author":"LM Tesfaw","year":"2022","unstructured":"Tesfaw LM, Muluneh EK (2022) Exploring and modeling recurrent birth events in ethiopia: EMDHS 2019. BMC Pregnancy Childbirth 22(1):617","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"13100_CR60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jsams.2012.03.017","volume":"15","author":"TJ Gabbett","year":"2012","unstructured":"Gabbett TJ, Ullah S, Finch CF (2012) Identifying risk factors for contact injury in professional rugby league players\u2013application of a frailty model for recurrent injury. J Sci Med Sport 15(6):496\u2013504","journal-title":"J Sci Med Sport"},{"key":"13100_CR61","unstructured":"Sousa-Ferreira I, Abreu AM (2019) A review of Cox\u2019 s model extensions for multiple events. In 2019 [cited 2024 Apr 12]. Available from: https:\/\/www.semanticscholar.org\/paper\/A-review-of-Cox%27-s-model-extensions-for-multiple-Sousa-Ferreira-Abreu\/2ab71f1438135a4a9fb3accfd3b3dab28cb74cf2"},{"issue":"3","key":"13100_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247\u2013256","journal-title":"Lancet Neurol"},{"issue":"8","key":"13100_CR63","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S et al (2022) Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 387(8):704\u2013714","journal-title":"N Engl J Med"},{"issue":"6","key":"13100_CR64","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 383(6):546\u201357","journal-title":"N Engl J Med."},{"issue":"17","key":"13100_CR65","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/bjsports-2011-090803","volume":"48","author":"S Ullah","year":"2014","unstructured":"Ullah S, Gabbett TJ, Finch CF (2014) Statistical modelling for recurrent events: an application to sports injuries. Br J Sports Med 48(17):1287\u20131293","journal-title":"Br J Sports Med"},{"issue":"10","key":"13100_CR66","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/sim.2298","volume":"25","author":"AV Olesen","year":"2006","unstructured":"Olesen AV, Parner ET (2006) Correcting for selection using frailty models. Stat Med 25(10):1672\u20131684","journal-title":"Stat Med"},{"issue":"2","key":"13100_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3111\/200710079089","volume":"10","author":"R Gani","year":"2007","unstructured":"Gani R, Nixon RM, Hughes S, Jackson CH (2007) Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis. J Med Econ 10(2):79\u201389","journal-title":"J Med Econ"},{"issue":"11","key":"13100_CR68","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli \u00d6 et al (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 80(11):1232\u20131245","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13100-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13100-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13100-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:04:38Z","timestamp":1747659878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13100-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["13100"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13100-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Main author and corresponding author received approval from C-path Institute to use the MSOAC placebo data. All data are fully anonymized and de-identified and ethical considerations have been met.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"371"}}